Trials / Completed
CompletedNCT00014729
Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- University of North Carolina · Academic / Other
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
OBJECTIVES: I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis bullosa.
Detailed description
PROTOCOL OUTLINE: Patients receive oral isotretinoin daily for 8 months in the absence of disease progression or unacceptable toxicity. Completion date provided represents the completion date of the grant per OOPD records
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | isotretinoin |
Timeline
- Start date
- 2000-10-01
- Completion
- 2002-09-01
- First posted
- 2001-04-11
- Last updated
- 2015-03-25
Source: ClinicalTrials.gov record NCT00014729. Inclusion in this directory is not an endorsement.